Duncan Barbara Gayle is a director of Atea Pharmaceuticals Inc.
Person profile
Roles
Atea Pharmaceuticals
Director
Fusion Pharmaceuticals
Director
Halozyme Therapeutics
Director
Jounce Therapeutics
Director
Address
New York, New York
Employees
SEC CIK
Latest filings (excl ownership)
No filings
Latest ownership filings
4
Ovid Therapeutics Inc.
26 Feb 24
4
Atea Pharmaceuticals, Inc.
21 Jun 23
4
Fusion Pharmaceuticals Inc.
14 Jun 23
4
HALOZYME THERAPEUTICS, INC.
9 May 23
4
Jounce Therapeutics, Inc.
4 May 23
4
Ovid Therapeutics Inc.
27 Feb 23
4
HALOZYME THERAPEUTICS, INC.
7 Feb 23
3
HALOZYME THERAPEUTICS, INC.
6 Feb 23
4
Adaptimmune Therapeutics PLC
1 Jul 22
4
Jounce Therapeutics, Inc.
28 Jun 22
Recent insider trades
Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Feb 24 | OVID Ovid Therapeutics | Stock Option Common Stock | Grant | Acquire A | No | No | 3.68 | 30,000 | 110.40 k | 30,000 |
16 Jun 23 | AVIR Atea Pharmaceuticals | Stock Option Common Stock | Grant | Acquire A | No | No | 4.12 | 46,750 | 192.61 k | 46,750 |
16 Jun 23 | AVIR Atea Pharmaceuticals | RSU Common Stock | Grant | Acquire A | No | No | 0 | 33,150 | 0.00 | 33,150 |
14 Jun 23 | FUSN Fusion Pharmaceuticals | Stock Opion Common Stock | Grant | Acquire A | No | No | 4.64 | 17,000 | 78.88 k | 17,000 |
5 May 23 | HALO Halozyme Therapeutics | Common Stock | Grant | Acquire A | No | No | 0 | 8,065 | 0.00 | 9,253 |
5 May 23 | HALO Halozyme Therapeutics | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 31 | 11,371 | 352.50 k | 11,371 |
3 May 23 | JNCE Jounce Therapeutics | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.8 | 20,000 | 56.00 k | 0 |
3 May 23 | JNCE Jounce Therapeutics | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 7.27 | 15,700 | 114.14 k | 0 |
3 May 23 | JNCE Jounce Therapeutics | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 7.58 | 15,700 | 119.01 k | 0 |
3 May 23 | JNCE Jounce Therapeutics | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.46 | 15,700 | 70.02 k | 0 |